Indivior PLC
INDV
Company Profile
Business description
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
Contact
10710 Midlothian Turnpike
Suite 125
North Chesterfield
RichmondVA23235
USAT: +1 804 379-1040
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,051
Stocks News & Analysis
stocks
Is this ASX share a value trap or bargain?
Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
stocks
Major ASX listed miners overvalued
We’ve adjusted our fair values after updating our commodity price assumptions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.60 | 19.70 | -0.22% |
| CAC 40 | 8,021.22 | 90.80 | -1.12% |
| DAX 40 | 24,606.64 | 352.42 | -1.41% |
| Dow JONES (US) | 49,359.33 | 83.11 | -0.17% |
| FTSE 100 | 10,083.69 | 111.66 | -1.10% |
| HKSE | 26,487.51 | 76.39 | -0.29% |
| NASDAQ | 23,515.39 | 14.63 | -0.06% |
| Nikkei 225 | 52,991.10 | 592.47 | -1.11% |
| NZX 50 Index | 13,573.93 | 6.36 | -0.05% |
| S&P 500 | 6,940.01 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,815.90 | 20.70 | -0.23% |
| SSE Composite Index | 4,113.65 | 0.35 | -0.01% |